@article {SCHNEEWEISS967, author = {ANDREAS SCHNEEWEISS and FRANK F{\"O}RSTER and HANS TESCH and BAHRIYE AKTAS and OLEG GLUZ and MATTHIAS GEBERTH and MARTIN M. HERTZ-EICHENRODE and WINFRIED SCH{\"O}NEGG and CLAUDIA SCHUMACHER and ANDREAS KUTSCHEIDT and CLAUDIA KIEWITZ and SANDRA KLAWITTER and MARCUS SCHMIDT}, title = {First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study}, volume = {36}, number = {3}, pages = {967--974}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-points were safety and efficacy [response rate, progression-free survival (PFS) and overall survival (OS)]. Results: Between May 2007 and September 2009, 865 patients received first-line bevacizumab plus paclitaxel for mBC, of whom 16\% were aged >=70 years and 9\% had ECOG performance status of 2 or more. At data cut-off (median of 15.9 months{\textquoteright} follow-up), the median PFS was 9.6 months [95\% confidence interval (CI)=9.0-10.4 months] and the median OS was 21.6 months (95\% CI=19.4-23.5 months). The most common non-haematological adverse drug reactions of grade 3 or more were pain (9\%), hypertension (5\%), sensory neuropathy (3\%) and proteinuria (3\%). Prolonged bevacizumab was well-tolerated. Conclusion: The efficacy and safety of first-line bevacizumab{\textendash}paclitaxel in routine oncology practice is consistent with results from randomized trials.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/3/967}, eprint = {https://ar.iiarjournals.org/content/36/3/967.full.pdf}, journal = {Anticancer Research} }